INmune Bio Reports Q2 2026 Results and Pipeline Progress
BOCA RATON, Fla., August 6, 2026 INmune Bio Inc. reported its second quarter 2026 financial results while highlighting significant...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOCA RATON, Fla., August 6, 2026 INmune Bio Inc. reported its second quarter 2026 financial results while highlighting significant...
INmune Bio, BOCA RATON, Fla., July 9, 2026 INmune Bio Inc. announced positive new imaging findings from its Phase...
BOCA RATON, Fla., May 15, 2026 INmune Bio announced the publication of positive Phase 2 MINDFuL trial results for...
